Welcome to our dedicated page for Structure Therapeutics American Depositary Shares news (Ticker: GPCR), a resource for investors and traders seeking the latest updates and insights on Structure Therapeutics American Depositary Shares stock.
Structure Therapeutics Inc. (NASDAQ: GPCR) is a clinical-stage biopharmaceutical company revolutionizing the treatment of chronic diseases through innovative oral therapeutics. The company’s lead product candidate, GSBR-1290, is an oral small molecule agonist targeting the glucagon-like-peptide-1 receptor (GLP-1R), a proven drug target for type-2 diabetes and obesity. By focusing on GPCRs, Structure Therapeutics aims to address significant unmet medical needs in metabolic and cardiopulmonary diseases.
In recent developments, Structure Therapeutics reported promising results from its Phase 1b study of GSBR-1290, showcasing its potential as a differentiated oral GLP-1 receptor agonist. The company is advancing GSBR-1290 into Phase 2 trials, aiming to further demonstrate its efficacy and safety in treating type-2 diabetes and obesity. Additionally, the company is developing other oral small-molecule therapeutics, including ANPA-0073 and LTSE-2578, targeting pulmonary and cardiovascular diseases.
Financially, Structure Therapeutics is in a robust position, with a cash reserve of $205.4 million as of September 30, 2023, and an additional $300 million raised through private placement in October 2023. This strong financial backing will support the advancement of the company’s clinical programs and achieve key milestones through 2026.
Structure Therapeutics' commitment to scientific innovation is evident in its next-generation structure-based drug discovery platform, which underpins its GPCR-targeted pipeline. The company’s strategic partnerships with leading healthcare investors further bolster its mission to deliver transformative oral therapies to patients worldwide.
For more information, visit www.structuretx.com.
Structure Therapeutics (NASDAQ: GPCR) has announced multiple poster presentations at ObesityWeek® 2024, scheduled for November 3-6, 2024 in San Antonio, TX. The company will present three posters focusing on obesity treatment innovations:
1. A presentation on novel oral small molecule dual amylin and calcitonin receptor agonists for obesity treatment
2. Research on drug design principles and PK/PD of GSBR-1290, a small molecule GLP-1RA
3. Clinical results showing significant weight changes at 12 weeks with GSBR-1290
All presentations will take place in Exhibit Hall 4, with specific sessions scheduled for November 3-4.
Structure Therapeutics Inc. (NASDAQ: GPCR) has announced key leadership changes to drive its next phase of development. Blai Coll, M.D., Ph.D., has been promoted to Chief Medical Officer, replacing Mark Bach, M.D., Ph.D., effective September 18, 2024. Dr. Coll has been leading the GSBR-1290 program, an oral small molecule GLP-1 agonist for obesity, set to enter Phase 2b clinical trials in Q4 2024.
Additionally, Ashley Hall, J.D., has been appointed as Chief Development Officer, a new position overseeing clinical development operations, project management, regulatory affairs, and quality assurance. These appointments aim to strengthen the company's position as it advances its clinical programs, including the development of an oral amylin compound.
Structure Therapeutics Inc. (NASDAQ: GPCR) has appointed Angus C. Russell to its board of directors. Mr. Russell, former CEO of Shire plc, brings over 30 years of experience in the global biopharmaceutical industry. This appointment comes as Structure prepares to advance its oral small molecule GLP-1 agonist, GSBR-1290, into late-stage clinical development for obesity. CEO Raymond Stevens highlighted Russell's expertise in strategy, finance, operations, and commercialization as valuable assets for the company's growth. Russell expressed enthusiasm for Structure's potential in the obesity market, particularly with GSBR-1290 and its pipeline of oral small molecule therapeutics.
Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company focusing on novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, has announced its participation in two upcoming investor conferences in September 2024:
1. Morgan Stanley 22nd Annual Global Healthcare Conference: Fireside chat on Thursday, September 5 at 10:00 a.m. EDT
2. Cantor Fitzgerald Global Healthcare Conference 2024: Fireside chat on Thursday, September 19 at 9:10 a.m. EDT
Live and archived webcasts of both fireside chats will be available on the company's website, with replays accessible for 90 days after the events.
Structure Therapeutics (NASDAQ: GPCR) reported Q2 2024 financial results and recent highlights. Key points include:
1. GSBR-1290 Phase 2b obesity study on track for Q4 2024 initiation.
2. Oral small molecule amylin receptor agonist development candidate expected in Q4 2024.
3. Strong financial position with $927.1 million cash balance, funding operations through at least 2027.
4. Q2 2024 R&D expenses increased to $22.1 million from $19.4 million in Q2 2023.
5. Q2 2024 G&A expenses rose to $11.3 million from $6.6 million in Q2 2023.
6. Net loss for Q2 2024 was $26.0 million, compared to $23.3 million in Q2 2023.
7. GSBR-1290 Phase 2a results showed 6.2% placebo-adjusted mean weight loss at 12 weeks.
Structure Therapeutics (NASDAQ: GPCR) announced the closing of its upsized public offering of 10,427,017 American depositary shares (ADSs), each representing three ordinary shares, at $52.50 per ADS. The offering, which included the full exercise of the underwriters' option to purchase an additional 1,360,045 ADSs, generated gross proceeds of around $547.4 million. The proceeds are subject to underwriting discounts, commissions, and offering expenses. The offering was managed by Goldman Sachs, Morgan Stanley, Jefferies, Leerink Partners, Guggenheim Securities, and BMO Capital Markets. The registration statements for the securities became effective on June 5, 2024.
Structure Therapeutics, a clinical-stage biopharmaceutical company (NASDAQ: GPCR), announced the pricing of its upsized public offering. The company is set to offer 9,066,972 American Depositary Shares (ADS) at $52.50 each, aiming for gross proceeds of approximately $476 million before deductions. An additional 1,360,045 ADSs may be purchased by underwriters within 30 days. The offering, managed by major financial institutions including Goldman Sachs and Morgan Stanley, will close on June 7, 2024, contingent on standard conditions.
Structure Therapeutics, a clinical-stage biopharmaceutical company (NASDAQ: GPCR), has filed a Form S-1 registration statement with the SEC for a proposed public offering of 8,000,000 American depositary shares (ADSs). Each ADS represents three ordinary shares. The company may also offer pre-funded warrants in lieu of ADSs. The price per pre-funded warrant will be the ADS price minus $0.0001. The underwriters have a 30-day option to purchase up to an additional 1,200,000 ADSs. The offering's completion depends on market conditions and other factors. Joint book-running managers include Goldman Sachs, Morgan Stanley, Jefferies, Leerink Partners, Guggenheim Securities, and BMO Capital Markets.
Structure Therapeutics announced positive topline data from its Phase 2a study and capsule to tablet PK study for its oral GLP-1 receptor agonist, GSBR-1290. The Phase 2a study showed a statistically significant placebo-adjusted mean weight loss of 6.2% at 12 weeks, while the capsule to tablet PK study achieved up to a 6.9% weight loss. GSBR-1290 demonstrated favorable safety and tolerability with low discontinuation rates due to adverse events.
The company plans to start a 36-week Phase 2b study in the fourth quarter of 2024, following an IND submission to the FDA in the third quarter. The new study will use the tablet formulation and involve approximately 300 participants.
These results underscore the potential of GSBR-1290 as a treatment for obesity, with benefits including once-daily dosing and favorable safety profiles. Future development plans include exploring higher doses and combination therapies.
Structure Therapeutics Inc., a biopharmaceutical company, reported financial results for Q1 2024, highlighting upcoming milestones such as data release for obesity drug GSBR-1290 and plans for Phase 2b study. The company aims to address obesity epidemic with its oral small molecule GLP-1 receptor agonist. Positive financial highlights include a cash position of $436.4 million, funding projected operations through 2026.
FAQ
What is the current stock price of Structure Therapeutics American Depositary Shares (GPCR)?
What is the market cap of Structure Therapeutics American Depositary Shares (GPCR)?
What is Structure Therapeutics Inc.'s main focus?
What is GSBR-1290?
What recent financial achievements has Structure Therapeutics made?
What are the other therapeutic candidates in the pipeline?
How does Structure Therapeutics plan to use the proceeds from the recent financing?
What makes Structure Therapeutics' drug discovery platform unique?
Who are the key partners in the recent private placement financing?
What are the company's plans for GSBR-1290 in 2024?
How is Structure Therapeutics addressing the unmet medical needs?